GSK plc — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
11-K
13F-HR
20-F
20-F/A
25-NSE
3
3/A
4
4/A
424B2
424B3
5
6-K
6-K/A
8-A12B
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3/A
F-3ASR
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
POS AM
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G/A
SD
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001495 | Feb 24, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001477 | Feb 24, 2026 | — |
| SC TO-T/A | SC TO-T/A | 0001193125-26-065083 | Feb 24, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001438 | Feb 23, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001425 | Feb 20, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001411 | Feb 20, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001380 | Feb 19, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001372 | Feb 19, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001330 | Feb 18, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001297 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001295 | Feb 17, 2026 | — |
| 6-K | GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME | 0001654954-26-001288 | Feb 17, 2026 | — |
| 6-K | EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | 0001654954-26-001276 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001267 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001265 | Feb 17, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001262 | Feb 17, 2026 | — |
| 13F-HR | — | 0001999371-26-003198 | Feb 12, 2026 | Dec 31, 2025 |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001125 | Feb 11, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001123 | Feb 11, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001116 | Feb 11, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001113 | Feb 11, 2026 | — |
| 6-K | CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION | 0001654954-26-001068 | Feb 10, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001035 | Feb 9, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000976 | Feb 6, 2026 | — |
| 6-K | NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION | 0001654954-26-000970 | Feb 6, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000949 | Feb 5, 2026 | — |
| 6-K | FINAL RESULTS | 0001654954-26-000892 | Feb 4, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000829 | Feb 2, 2026 | — |
| SC TO-T | SC TO-T | 0001193125-26-032610 | Feb 2, 2026 | — |
| 6-K | EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ | 0001654954-26-000581 | Jan 26, 2026 | — |
| SC TO-C | SC TO-C | 0001193125-26-016553 | Jan 20, 2026 | — |
| SC TO-C | SC TO-C | 0001193125-26-016042 | Jan 20, 2026 | — |
| 6-K | GSK TO ACQUIRE RAPT THERAPEUTICS | 0001654954-26-000470 | Jan 20, 2026 | — |
| 6-K | AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING | 0001654954-26-000468 | Jan 20, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000417 | Jan 16, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000375 | Jan 15, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000324 | Jan 13, 2026 | — |
| 6-K | EC APPROVAL OF SHINGRIX PFS | 0001654954-26-000138 | Jan 7, 2026 | — |
| 6-K | POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN | 0001654954-26-000136 | Jan 7, 2026 | — |
| 6-K | EXDENSUR APPROVED IN JAPAN | 0001654954-26-000107 | Jan 6, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000071 | Jan 5, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000061 | Jan 5, 2026 | — |
| 6-K | NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA | 0001654954-26-000056 | Jan 5, 2026 | — |
| 6-K | GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US | 0001654954-25-014268 | Dec 23, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014212 | Dec 22, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014156 | Dec 22, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014129 | Dec 19, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014074 | Dec 18, 2025 | — |
| 6-K | EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA | 0001654954-25-014033 | Dec 17, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014027 | Dec 17, 2025 | — |